Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P62277

UPID:
RS13_HUMAN

ALTERNATIVE NAMES:
40S ribosomal protein S13

ALTERNATIVE UPACC:
P62277; B2R549; P19116; Q02546; Q29200; Q498Y0

BACKGROUND:
Small ribosomal subunit protein uS15, known alternatively as 40S ribosomal protein S13, is a key player in the cell's protein manufacturing process. It contributes to the assembly of the small eukaryotic ribosomal subunit, working alongside ribosome biogenesis factors and an RNA chaperone. This collaboration ensures the precise folding and modification of pre-rRNA, a critical step in the formation of functional ribosomes.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Small ribosomal subunit protein uS15 offers a promising pathway to novel therapeutic avenues. Given its essential role in ribosomal assembly and protein synthesis, targeting this protein could lead to breakthroughs in treating conditions linked to abnormal protein production.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.